STOCK TITAN
  1. Home
  2. Sec-filings
  3. RAPP
  4. [Form 4] Rapport Therapeutics, Inc. Insider Trading Activity

Rapport Therapeutics (RAPP) CEO sells 18,921 shares in pre-arranged trade

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. (RAPP) reported that Chief Executive Officer and director Abraham Ceesay sold 18,921 shares of common stock on August 25, 2026 in an open-market transaction at a weighted average price of $49.5723 per share, pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. Following this sale, he directly holds 467,187 shares of common stock, and also has indirect ownership of 81,729 shares through the Ceesay Family Irrevocable Trust and 20,729 shares through the Dorothy Ceesay Irrevocable Trust.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Ceesay Abraham
Role Chief Executive Officer
Sold 18,921 shs ($938K)
Type Security Shares Price Value
Sale Common Stock F1, F2 18,921 $49.5723 $938K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 467,187 shares (Direct); Common Stock — 81,729 shares (Indirect, By Ceesay Family Irrevocable Trust); Common Stock — 20,729 shares (Indirect, By Dorothy Ceesay Irrevocable Trust)
Footnotes (2)
  1. F1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.03 to $50.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Shares sold 18,921 shares of Common Stock Sale on August 25, 2026 by Abraham Ceesay
Weighted average sale price $49.5723 per share Open-market sale on August 25, 2026
Sale price range $49.03 to $50.03 per share Multiple transactions included in the reported sale
Direct holdings after transaction 467,187 shares of Common Stock Direct ownership by Abraham Ceesay following the sale
Indirect holdings – Ceesay Family Irrevocable Trust 81,729 shares of Common Stock Indirect ownership reported as held by Ceesay Family Irrevocable Trust
Indirect holdings – Dorothy Ceesay Irrevocable Trust 20,729 shares of Common Stock Indirect ownership reported as held by Dorothy Ceesay Irrevocable Trust
Rule 10b5-1 plan adoption date March 27, 2026 Date the trading plans governing the reported sale were adopted
Rule 10b5-1 trading plans regulatory
"transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading"
Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect ownership financial
"ownership_type":"indirect","ownership_code":"I""
open market or private transaction market
"transaction_code_description":"Sale in open market or private transaction""

FAQ

What insider transaction did RAPP report for Abraham Ceesay on this Form 4?
The filing reports that Abraham Ceesay sold 18,921 shares of Rapport Therapeutics common stock on August 25, 2026 in an open-market transaction at a weighted average price of $49.5723 per share.

Was the RAPP insider sale by Abraham Ceesay under a Rule 10b5-1 plan?
Yes. The Form 4 states that the transactions were effected pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026, indicating they were pre-arranged under that plan.

How many RAPP shares does Abraham Ceesay hold directly after this transaction?
After the reported sale, Abraham Ceesay directly holds 467,187 shares of Rapport Therapeutics common stock, as shown in the post-transaction ownership column.

What indirect RAPP shareholdings are reported for Abraham Ceesay?
The Form 4 shows indirect ownership of 81,729 shares held by Ceesay Family Irrevocable Trust and 20,729 shares held by Dorothy Ceesay Irrevocable Trust, both reported as indirect holdings.

What price range did the RAPP shares sell for in the reported transaction?
A footnote explains that the reported $49.5723 is a weighted average price, with shares sold in multiple transactions at prices ranging from $49.03 to $50.03, inclusive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ceesay Abraham
(Last)(First)(Middle)
RAPPORT THERAPEUTICS, INC.
99 HIGH STREET, SUITE 2100
(Street)
BOSTON MASSACHUSETTS 02110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/25/2026S(1)18,921D$49.5723(2)467,187D
Common Stock81,729IBy Ceesay Family Irrevocable Trust
Common Stock20,729IBy Dorothy Ceesay Irrevocable Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.03 to $50.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
/s/ Troy Ignelzi, Attorney-in-Fact08/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR